Leukemia Research
Volume 33, Issue 5 , Pages 717-727 , May 2009

Converting cell lines representing hematological malignancies from glucocorticoid-resistant to glucocorticoid-sensitive: Signaling pathway interactions

Received 12 May 2008 ,Revised 27 August 2008 ,Accepted 6 October 2008.

References 

  1. Kyriakis JM. MAP kinases and the regulation of nuclear receptors. Sci STKE. 2000;48:1–4
  2. Bruna A, Nicolas M, Munoz A, Kyriakis JM, Caelles C. Glucocorticoid receptor-JNK interaction mediates inhibition of the JNK pathway by glucocorticoids. EMBO J. 2003;22:6035–6044
  3. Rogatsky I, Logan SK, Garabedian MJ. Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. Proc Natl Acad Sci USA. 1998;95:2050–2055
  4. Medh RD, Saeed MF, Johnson BH, Thompson EB. Resistance of human leukemic CEM-C1 cells is overcome by synergism between glucocorticoid and protein kinase A pathways: correlation with c-Myc suppression. Cancer Res. 1998;58:3684–3693
  5. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 2004;23:2838–2849
  6. Miller AL, Webb MS, Copik AJ, Wang Y, Johnson BH, Kumar R, et al. p38 MAP kinase is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol Endocrinol. 2005;19:1569–1583
  7. Miller AL, Garza SA, Johnson BH, Thompson EB. Pathway interactions between MAPKs, mTOR, PKA, and the glucocorticoid receptor in lymphoid cells. Cancer Cell Int. 2007;3–7
  8. Stromberg T, Dimberg A, Hammarberg A, Carlson K, Osterborg A, Nilsson K, et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood. 2004;103:3138–3147
  9. Thompson EB. Apoptosis and steroid hormones. Mol Endocrinol. 1994;8:665–673
  10. Medh RD, Webb MS, Miller AL, Johnson BJ, Fofanov Y, Li T, et al. Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis. Genomics. 2003;81:543–555
  11. Zhou F, Thompson EB. Role of c-jun induction in the glucocorticoid-evoked apoptotic pathway in human leukemic lymphoblasts. Mol Endocrinol. 1996;10:306–316
  12. Harmon JM, Eisen HJ, Brower ST, Simons SS, Langley CL, Thompson EB. Identification of human leukemic glucocorticoid receptors using affinity labeling and anti-human glucocorticoid receptor antibodies. Cancer Res. 1984;44:4540–4547
  13. Koeffler HP, Golde DW, Lippman ME. Glucocorticoid sensitivity and receptors in cells of human myelogenous leukemia lines. Cancer Res. 1980;40:563–566
  14. Ashraf J, Thompson EB. Identification of the activation-labile gene: a single point mutation in the human glucocorticoid receptor presents as two distinct receptor phenotypes. Mol Endocrinol. 1993;7:631–642
  15. Tanaka T, Okabe T, Gondo S, Fukuda M, Yamamoto M, Umemura T, et al. Modification of glucocorticoid sensitivity by MAP kinase signaling pathways in glucocorticoid-induced T-cell apoptosis. Exp Hematol. 2006;34:1542–1552
  16. Ji Z, Mei FC, Johnson BH, Thompson EB, Cheng X. PKA, not EPAC, suppresses hedgehog activity and regulates glucocorticoid sensitivity in acute lymphoblastic leukemia cells. J Biol Chem. 2007;282(52):37370–37377
  17. Medh RD, Wang A, Zhou F, Thompson EB. Constitutive expression of ectopic c-Myc delays glucocorticoid-evoked apoptosis of human leukemic CEM-C7 cells. Oncogene. 2001;20(34):4629–4639
  18. Ramdas J, Liu W, Harmon JM. Glucocorticoid-induced cell death requires autoinduction of glucocorticoid receptor expression in human leukemic T cells. Cancer Res. 1999;59:1378–1385
  19. Tonko M, Ausserlechner MJ, Bernhard D, Helmberg A, Kofler R. Gene expression profiles of proliferating vs. G1/G0 arrested human leukemia cells suggest a mechanism for glucocorticoid-induced apoptosis. FASEB J. 2001;15(3):693–699
  20. Webb MS, Miller AL, Johnson BH, Fofanov Y, Li T, Wood TG, et al. Gene networks in glucocorticoid-evoked apoptosis in leukemic cells. J Steroid Biochem Mol Biol. 2003;85(2–5):183–193
  21. Wang Z, Malone MH, He H, McColl KS, Distelhorst CW. Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J Biol Chem. 2003;278(26):23861–23867
  22. Katagiri S, Yonezawa T, Kuyama J, Kanayama Y, Nishida K, Abe T, et al. Two distinct human myeloma cell lines originating from one patient with myeloma. Int J Cancer. 1985;36(2):241–246
  23. Matsuoka Y, Moore GE, Yagi Y, Pressman D. Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc Soc Exp Biol Med. 1967;125(4):1246–1250
  24. Thompson EB, Nazareth LV, Thulasi R, Ashraf J, Harbour D, Johnson BH. Glucocorticoids in malignant lymphoid cells: gene regulation and the minimum receptor fragment for lysis. J Steroid Biochem Mol Biol. 1992;41(3–8):273–282
  25. Helmberg A, Auphan N, Caelles C, Karin M. Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor. EMBO J. 1995;14(3):452–460
  26. Leventhal BG. Glucocorticoid Receptors in lymphoid tumors. Cancer Res. 1981;41(11 Pt 2):4861–4862
  27. Gomi M, Moriwaki K, Katagiri S, Kurata Y, Thompson EB. Glucocorticoid effects on myeloma cells in culture: correlation of growth inhibition with induction of glucocorticoid receptor messenger RNA. Cancer Res. 1990;50:1873–1878
  28. Sasaki R, Mishima Y, Srivastava BI, Minowada J. Effect of Dexamethasone on the growth of human lymphoblastoid cell lines. Jpn J Med. 1982;21:89–95
  29. Kontula K, Paavonen T, Vuopio P, Andersson LC. Glucocorticoid receptors in hairy-cell leukemia. Int J Cancer. 1982;30:423–426
  30. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 1975;45:321–334
  31. Rousseau GR, Chambon P, Amar-Coster A. Glucocorticoid-receptor-mediated stimulation of 5′ nucleotidase in human lyphoblastoid IM-9 cells. FEBS Lett. 1980;121:249–252
  32. Sica G, Lama G, Tartaglione R, Picarrelli L, Frati L. Effects of natural β-interferon and recombinant α-2B-interferon on proliferation, glucocorticoid receptor content, and antigen expression in cultured HL-60 cells. Cancer. 1990;65:920–925
  33. Sinclair AJ, Jacquemin MG, Brooks L, Shanahan F, Brimmell M, Rowe M, et al. Reduced signal transduction through glucocorticoid receptor in Burkitt's lymphoma cell lines. Virology. 1994;199:338–353
  34. Srivastava MD, Anderson DJ. Progesterone receptor expression by human leukocyte cell lines: molecular mechanisms of cytokine suppression. Clin Exp Obstet Gynecol. 2007;34(1):14–24
  35. Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F, et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and surviving. Blood. 2003;101:278
  36. Gruol DJ, Rajah FM, Bourgeouis S. Cyclic AMP-dependent protein kinase modulation of the glucocorticoid-induced cytolytic response in murine T-lymphoma cells. Mol Endocrinol. 1989;3:2119–2127
  37. Itoh M, Adachi M, Yasui H, Takekawa M, Tanaka H, Imai K. Nuclear export of glucocorticoid receptor is enhanced by c-Jun N-terminal kinase-mediated phosphorylation. Mol Endocrinol. 2002;16(10):2382–2392
  38. Meyers JA, Taverna J, Chaves J, Makkinje A, Lerner A. Receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells phosphodiesterase 4 inhibitors augment levels of glucocorticoid. Clin Cancer Res. 2007;13:4920–4927
  39. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006;10(4):331–342
  40. Simons SS. How much is enough? Modulation of dose-response curve for steroid receptor-regulated gene expression by changing concentrations of transcription factor. Curr Top Med Chem. 2006;6(3):271–285
  41. Leung KT, Li K, Sai-Ming Sun S, Sheung Chan PK, Eng-Choon Ooi V, Chi-Ming Chiu L. Activation of the JNK pathway promotes phosphorylation and degradation of BimEL a novel mechanism of chemoresistance in T-cell acute lymphoblastic leukemia. Carcinogenesis 2007;Epub. PMID: 18174237.
  42. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther. 2007;6(8):2209–2219
  43. Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol. 2008;26(3):361–367

☆ Supported by Cancer grant NCI 2RO1 CA41407 to E. Brad Thompson.

PII: S0145-2126(08)00462-1

doi: 10.1016/j.leukres.2008.10.006

Leukemia Research
Volume 33, Issue 5 , Pages 717-727 , May 2009

Article Tools

* Image Usage & Resolution